- CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $240K into a new gene replacement therapy for CMT4A, with a ...
Read more ... - From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT
Finding Your Gene
Researchers have discovered over 120 genes linked to CMT; dozens were found with CMTA funding initiatives. Despite this, referred to as the “diagnostic gap,” more than 50% of all who have CMT Type ...
Read more ... - 2024 CMTA Patient & Research Summit Registration is Now Open
The 2024 CMTA Patient & Research Summit will take place on Friday, September 6th – Sunday, September 8th at the Denver Marriott West in Denver, Colorado. The CMTA Summit will offer life-improving presentations on living ...
Read more ... - CMTA Announces New Center of Excellence in the United Kingdom
The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments to patients and improving the lives of those living with Charcot-Marie-Tooth disease (CMT), is excited to announce ...
Read more ... - New Law Makes Flying Easier for People Living With Charcot-Marie-Tooth Disease
A partnership between the Charcot-Marie-Tooth Association (CMTA), Muscular Dystrophy Association (MDA), and other dedicated advocates has successfully passed a new law that will make flying easier for people living with Charcot-Marie-Tooth Disease (CMT).
Here ...
Read more ...